Return to Statistics Toolbox

Pathway mapping for Study ST003429

(Analysis All analyses used)
Select one or more experimental factors for Groups 1 and 2. The members of each group should be DIFFERENT.
Group1Experimental factorGroup2
Sample source:BT-474 breast cancer cells | Sample Type:Intracellular | Drug Treatment:0.1 uM Fasnall (3)
Sample source:BT-474 breast cancer cells | Sample Type:Intracellular | Drug Treatment:10 uM Fasnall (3)
Sample source:BT-474 breast cancer cells | Sample Type:Intracellular | Drug Treatment:1 uM Fasnall (3)
Sample source:BT-474 breast cancer cells | Sample Type:Intracellular | Drug Treatment:20 uM Fasnall (3)
Sample source:BT-474 breast cancer cells | Sample Type:Intracellular | Drug Treatment:40 uM Fasnall (3)
Sample source:BT-474 breast cancer cells | Sample Type:Intracellular | Drug Treatment:5 uM Fasnall (3)
Sample source:BT-474 breast cancer cells | Sample Type:Intracellular | Drug Treatment:Control (3)
Sample source:BT-474 breast cancer cells | Sample Type:Medium | Drug Treatment:0.1 uM Fasnall (3)
Sample source:BT-474 breast cancer cells | Sample Type:Medium | Drug Treatment:10 uM Fasnall (3)
Sample source:BT-474 breast cancer cells | Sample Type:Medium | Drug Treatment:1 uM Fasnall (3)
Sample source:BT-474 breast cancer cells | Sample Type:Medium | Drug Treatment:20 uM Fasnall (3)
Sample source:BT-474 breast cancer cells | Sample Type:Medium | Drug Treatment:40 uM Fasnall (3)
Sample source:BT-474 breast cancer cells | Sample Type:Medium | Drug Treatment:5 uM Fasnall (3)
Sample source:BT-474 breast cancer cells | Sample Type:Medium | Drug Treatment:Control (3)
Sample source:NA | Sample Type:Blank | Drug Treatment:NA (2)
Sample source:NA | Sample Type:Medium | Drug Treatment:10 uM Fasnall (3)
Sample source:NA | Sample Type:QC | Drug Treatment:NA (2)
Limit by pathway class:
Analysis:Combine data for all analyses?:     

  logo